Mereo BioPharma (UK) Performance
| 0A9G Stock | 3.55 0.15 4.41% |
The company secures a Beta (Market Risk) of -0.49, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Mereo BioPharma are expected to decrease at a much lower rate. During the bear market, Mereo BioPharma is likely to outperform the market. At this point, Mereo BioPharma Group has a negative expected return of -0.33%. Please make sure to verify Mereo BioPharma's treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if Mereo BioPharma Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference - StockTitan | 09/12/2024 |
2 | Marshall Wace LLP Purchases New Position in Mereo BioPharma Group plc - MarketBeat | 10/03/2024 |
3 | MREO Other Long-Term Liabilities 1.61 Mil - GuruFocus.com | 11/20/2024 |
| Other Cashflows From Financing Activities | 153 K |
Mereo |
Mereo BioPharma Relative Risk vs. Return Landscape
If you would invest 464.00 in Mereo BioPharma Group on September 2, 2024 and sell it today you would lose (109.00) from holding Mereo BioPharma Group or give up 23.49% of portfolio value over 90 days. Mereo BioPharma Group is generating negative expected returns and assumes 3.8306% volatility on return distribution over the 90 days horizon. Simply put, 34% of stocks are less volatile than Mereo, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Mereo BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mereo BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mereo BioPharma Group, and traders can use it to determine the average amount a Mereo BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0864
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 0A9G |
Estimated Market Risk
| 3.83 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mereo BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mereo BioPharma by adding Mereo BioPharma to a well-diversified portfolio.
Mereo BioPharma Fundamentals Growth
Mereo Stock prices reflect investors' perceptions of the future prospects and financial health of Mereo BioPharma, and Mereo BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mereo Stock performance.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (38.07) % | ||||
| Current Valuation | 2.68 B | ||||
| Revenue | 1000 K | ||||
| EBITDA | (37.48 M) | ||||
| Net Income | (34.2 M) | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (38.82 M) | ||||
| Earnings Per Share | (0.28) X | ||||
| Retained Earnings | (331.16 M) |
About Mereo BioPharma Performance
Assessing Mereo BioPharma's fundamental ratios provides investors with valuable insights into Mereo BioPharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mereo BioPharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Mereo BioPharma is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Mereo BioPharma Group performance evaluation
Checking the ongoing alerts about Mereo BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mereo BioPharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mereo BioPharma generated a negative expected return over the last 90 days | |
| Mereo BioPharma has high historical volatility and very poor performance | |
| Mereo BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1000 K. Net Loss for the year was (34.2 M) with profit before overhead, payroll, taxes, and interest of 936 K. | |
| Mereo BioPharma generates negative cash flow from operations | |
| About 68.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: MREO Other Long-Term Liabilities 1.61 Mil - GuruFocus.com |
- Analyzing Mereo BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mereo BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Mereo BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mereo BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mereo BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mereo BioPharma's stock. These opinions can provide insight into Mereo BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.